6505--Nicotine Lozenges MINI (VA-26-00020754) Effective 07/19/2026 to 07/18/2027
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NAC PHARMACEUTICALS (36E797)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36E79726R0007
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
This procurement notice announces the award of a contract for the supply of Nicotine Lozenges MINI, under solicitation number 36E79726R0007, with an effective period from July 19, 2026, through July 18, 2027. The contract is managed by the National Acquisition Center (NAC) Pharmaceuticals division, a federal office within the Department of Veterans Affairs (VA). The primary objective of this procurement is to ensure a reliable supply of pharmaceutical-grade nicotine lozenges, specifically the MINI formulation, to support the VA’s ongoing efforts in tobacco cessation programs for veterans.
The scope of this contract encompasses the manufacturing and delivery of nicotine lozenges that meet stringent pharmaceutical preparation standards, as classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version). The awarded contractor is expected to provide products that comply with all applicable federal regulations and VA-specific requirements, ensuring both efficacy and safety for end users. The deliverables include the timely and consistent supply of the specified nicotine lozenges throughout the contract period, supporting the VA’s mission to enhance the health and well-being of veterans.
Key requirements for this procurement include adherence to the product service code 6505, which covers drugs and biologicals, and compliance with all relevant quality assurance protocols. The contractor must demonstrate the capability to manufacture and distribute pharmaceutical preparations at scale, maintaining rigorous quality control and documentation practices. The contract does not specify any set-aside requirements or special considerations in the provided information.
The contracting activity is overseen by the Department of Veterans Affairs, with the NAC Pharmaceuticals office serving as the primary point of contact. Interested parties or stakeholders may direct inquiries to Billy Fong, the designated contact person, via email at [email protected] or by phone at 708-786-4992. Additional details and official documentation related to this award can be accessed through the SAM.gov opportunity portal using Opportunity ID 90f323f7e5694897aa98157e1445bfde.
This award notice is currently active and was posted on March 24, 2026. Contractors with expertise in pharmaceutical manufacturing, particularly those experienced in nicotine replacement therapies, may find this opportunity aligns with their capabilities and long-term strategic interests in supporting federal healthcare initiatives.